4.555USD-7.23%Mkt Cap: 373.23M USDP/E: —Last update: 2026-05-26
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product cand…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap373.23M USD
Enterprise Value238.24M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-247.30M USD
Revenue/Share—
Last Price4.555 USD
Fiscal Year EndMar 2025
MR QuarterDec 2025
Employees479
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS76029N1063
Valuation
P/E (Trailing)—
P/E (Forward)-2.51
PEG—
EV/EBITDA-0.75
EV/Revenue—
P/S—
P/B1.97
EPS (TTM)-3.44
EPS (Forward)-2.08
52W Range
1.50026% of range13.24
52W High13.24 USD
52W Low1.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.47%
ROA-44.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-192.25M USD
CapEx (TTM)6.69M USD
FCF Margin—
FCF Yield-46.29%
Net Debt-192.79M USD
Net Debt/EBITDA0.60
Balance Sheet
Debt/Equity0.18
Current Ratio5.60
Quick Ratio5.43
Book Value/Sh2.644 USD
Cash/Share3.259 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.500 USD
Target Range1.000 USD – 10.00 USD
# Analysts6
Ownership
Shares Out.82.57M
Float58.46M
Insiders2.62%
Institutions89.86%
Short Interest
Short Ratio2.1d
Short % Float45.92%
Short % Out.25.62%
Shares Short21.16M
Short (prev mo.)16.34M
Technical
SMA 504.886 (-6.8%)
SMA 2006.784 (-32.9%)
Beta0.12
S&P 52W Chg28.31%
Avg Vol (30d)8.06M
Avg Vol (10d)8.56M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—